Efficacy and safety of telaprevir- and simeprevir-based triple therapies for older patients with chronic hepatitis C

Figure 3 Rates of sustained virological response to telaprevir and simeprevir by interleukin 28B single-nucleotide polymorphism. Percentages indicate the proportion of patients with undetectable serum hepatitis C virus RNA levels at 24 wk after the end of treatment. Patient numbers are shown in parenthesis. TT, interleukin 28B (IL28B) (rs8099917) TT-genotype; non-TT, IL28B TG/GG-genotypes ^aP = 0.038 (compared to older patients with the IL28B TT-genotype). ^bP = 0.005 (compared to older patients with the IL28B TT-genotype). TVR: Telaprevir; SMV: Simeprevir; SVR24: Sustained virological response defined as undetectable serum HCV RNA at 24 wk after the end of treatment.